In this paper we report an inhibitor antibody to factor XI (FXI) in a woman with severe inherited FXI deficiency, induced by FXI present in an Rh immune globulin preparation. The patient is homozygous for the Glu117Stop mutation, associated with a FXI level of less than 1U/dL.
Introduction
Inherited factor XI (FXI) deficiency is an injury-related bleeding disorder affecting mainly individuals homozygous or compound heterozygous for mutations in the FXI gene. The disorder is particularly common in Ashkenazi and Iraqi Jews 1 . Patients with severe inherited FXI deficiency can develop an inhibitor to FXI 2 , which complicates their clinical course. Although spontaneous bleeding in FXI inhibitor patients is uncommon, trauma or surgery in such patients can be accompanied by excessive bleeding, manageable only by infusion of activated prothrombin complex concentrate or recombinant factor VIIa. The trigger for development of an inhibitor in 22 previously described or reviewed cases was exposure to blood products and 10 patients genotyped were homozygous for Glu117stop mutation with baseline FXI levels of < 1U/dL 2 .
In this report we describe a patient with severe inherited FXI deficiency who developed an inhibitor following injections of Rh immune globulin. We suspected that the Rh immune globulin contained FXI which elicited the immune response. Herein, we present the characterization of the inhibitor and an analysis of several Rh immune globulin preparations, including the suspect product, for the presence of
FXI.
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Patient, materials and methods

The Human Subject Ethics Committee of the Sheba Medical
Center approved the study. Informed consent was provided according to the Declaration of Helsinki.
The patient is a 34 year old Canadian-born woman who has had no bleeding tendency except for heavy menstrual flow since menarche. 
Results and Discussion
Genotyping analysis disclosed that the patient was homozygous for the Glu117stop mutation, one of the two FXI mutations common in Jews 1 . The patient is non-Jewish Italian, and this population also harbors this mutation, with a haplotype identical to the Jewish haplotype 4 . The patient is exceptional among previously described patients with inherited FXI deficiency and an inhibitor, because she has never been exposed to blood products. Since FXI co-purifies with immunoglobulins 
